Ildong Pharmaceutical Co., Ltd. (249420.KS)
KRW 11350.0
(-5.42%)
KRW 11350.0
(-5.42%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 600.75 Billion KRW | -5.8% |
| 2022 | 637.71 Billion KRW | 13.85% |
| 2021 | 560.13 Billion KRW | -0.3% |
| 2020 | 561.84 Billion KRW | 8.58% |
| 2019 | 517.46 Billion KRW | 2.69% |
| 2018 | 503.9 Billion KRW | 9.39% |
| 2017 | 460.65 Billion KRW | 128.79% |
| 2016 | 201.34 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 152.14 Billion KRW | 0.69% |
| 2024 Q3 | 155.94 Billion KRW | 2.5% |
| 2024 Q1 | 151.09 Billion KRW | 0.01% |
| 2023 Q2 | 154.08 Billion KRW | 5.5% |
| 2023 Q3 | 149.53 Billion KRW | -2.96% |
| 2023 Q4 | 151.08 Billion KRW | 1.04% |
| 2023 FY | 600.75 Billion KRW | -5.8% |
| 2023 Q1 | 146.05 Billion KRW | -3.87% |
| 2022 Q4 | 151.93 Billion KRW | -7.15% |
| 2022 Q3 | 163.63 Billion KRW | 0.7% |
| 2022 Q2 | 162.49 Billion KRW | 1.78% |
| 2022 Q1 | 159.64 Billion KRW | 11.87% |
| 2022 FY | 637.71 Billion KRW | 13.85% |
| 2021 Q4 | 142.7 Billion KRW | 0.13% |
| 2021 Q2 | 141.64 Billion KRW | 6.28% |
| 2021 Q3 | 142.51 Billion KRW | 0.61% |
| 2021 FY | 560.13 Billion KRW | -0.3% |
| 2021 Q1 | 133.26 Billion KRW | -3.96% |
| 2020 FY | 561.84 Billion KRW | 8.58% |
| 2020 Q4 | 138.76 Billion KRW | -5.49% |
| 2020 Q3 | 146.81 Billion KRW | 6.77% |
| 2020 Q1 | 138.75 Billion KRW | 13.93% |
| 2020 Q2 | 137.51 Billion KRW | -0.9% |
| 2019 FY | 517.46 Billion KRW | 2.69% |
| 2019 Q2 | 136.65 Billion KRW | 5.74% |
| 2019 Q3 | 129.77 Billion KRW | -5.03% |
| 2019 Q4 | 121.79 Billion KRW | -6.15% |
| 2019 Q1 | 129.23 Billion KRW | -1.29% |
| 2018 Q4 | 130.92 Billion KRW | 2.09% |
| 2018 Q1 | 119.03 Billion KRW | 4.83% |
| 2018 Q2 | 125.7 Billion KRW | 5.6% |
| 2018 FY | 503.9 Billion KRW | 9.39% |
| 2018 Q3 | 128.24 Billion KRW | 2.02% |
| 2017 Q3 | 127.96 Billion KRW | 13.79% |
| 2017 Q2 | 112.45 Billion KRW | 5.41% |
| 2017 FY | 460.65 Billion KRW | 128.79% |
| 2017 Q4 | 113.55 Billion KRW | -11.26% |
| 2017 Q1 | 106.67 Billion KRW | -12.72% |
| 2016 Q4 | 122.22 Billion KRW | 54.49% |
| 2016 FY | 201.34 Billion KRW | 0.0% |
| 2016 Q3 | 79.11 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -337.84% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 46.93% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 5.903% |
| HANDOK Inc. | 522.74 Billion KRW | -14.925% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -343.781% |
| Yuhan Corporation | 1858.98 Billion KRW | 67.684% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 9.522% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1056.303% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 59.705% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -345.303% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -62.131% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -578.105% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -254.289% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -167.65% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -337.84% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -669.677% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -297.666% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -587.652% |
| JW Holdings Corporation | 928.07 Billion KRW | 35.268% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 64.014% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 19.741% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -200.036% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -232.346% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -205.969% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 17.296% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -337.84% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 60.332% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 56.319% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 19.741% |
| Yuhan Corporation | 1858.98 Billion KRW | 67.684% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 24.406% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -155.748% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -1.041% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 19.741% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -105.648% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -115.369% |
| CKD Bio Corp. | 160.35 Billion KRW | -274.648% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -14.006% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -66.365% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -160.753% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -200.036% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 31.715% |
| Boryung Corporation | 859.62 Billion KRW | 30.114% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -377.064% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -62.131% |
| JW Lifescience Corporation | 206.86 Billion KRW | -190.417% |